Astrana Health, Inc. 10-K Analysis & Summary – 3/14/2025

⚠️This is not investment advice.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️

Filing date:

03/14/2025


TLDR:

ELI5:

Astrana Health, a healthcare company, made more money this year but earned less profit overall. They’re buying another company, which could be risky, and they need to protect their data from hackers.


Accession #:

0000950170-25-039122

Published on

Analyst Summary

  • Total revenue increased by 47% from 2023 to 2024, driven by capitation revenue and risk pool settlements.
  • Operating expenses increased by 49%, primarily due to cost of services.
  • Net income attributable to Astrana Health, Inc. decreased by 29% from 2023 to 2024, while Adjusted EBITDA increased by 16%.
  • Adjusted EBITDA Margin decreased to 8% in 2024 from 11% in 2023.
  • Cash flow from operating activities decreased, while cash flow from financing activities increased; investing activities used significantly more cash due to acquisitions.
  • Gross Profit Margin decreased from 20.53% in 2023 to 14.23% in 2024.
  • Operating Profit Margin decreased from 6.10% in 2023 to 4.39% in 2024.
  • Net Profit Margin decreased from 4.17% in 2023 to 2.45% in 2024.
  • Return on Assets (ROA) decreased from 6.20% in 2023 to 3.69% in 2024.
  • Return on Equity (ROE) decreased from 9.85% in 2023 to 6.97% in 2024.
  • Basic Earnings Per Share (EPS) decreased from $1.30 in 2023 to $0.91 in 2024.
  • Diluted Earnings Per Share (EPS) decreased from $1.29 in 2023 to $0.90 in 2024.
  • Current Ratio decreased from 2.11 in 2023 to 1.75 in 2024.
  • Quick Ratio decreased from 1.22 in 2023 to 1.17 in 2024.
  • Cash Ratio decreased from 1.36 in 2023 to 0.79 in 2024.
  • Debt-to-Equity Ratio increased from 0.46 in 2023 to 0.61 in 2024.
  • Debt-to-Assets Ratio increased from 0.30 in 2023 to 0.32 in 2024.
  • Interest Coverage Ratio decreased from 6.57 in 2023 to 2.70 in 2024.
  • Asset Turnover increased from 1.49 in 2023 to 1.50 in 2024.
  • Revenue Growth increased by 47% from 2023 to 2024.
  • Net Income Growth decreased by -14% from 2023 to 2024.
  • EPS Growth decreased by -30% from 2023 to 2024.

Opportunities and Risks

  • Proposed Acquisition of Prospect: The acquisition is subject to regulatory approvals and bankruptcy court approval, creating uncertainty. Increased indebtedness to finance the transaction could limit financial flexibility.
  • Regulatory Compliance: The healthcare industry is heavily regulated, and non-compliance could result in penalties. Corporate practice of medicine laws could restrict the company’s business model.
  • Cybersecurity: Breaches of information security systems could lead to data exposure and disruption of business operations.
  • ACO REACH Model: Uncertainties in the design and administration of the ACO REACH Model could negatively impact results.
  • Reliance on Key Payers: A limited number of payers represent a significant portion of net revenue, creating concentration risk.
  • Shift to Value-Based Care: The industry’s move towards value-based and results-oriented models presents growth opportunities.
  • Integrated Health Network: The company’s integrated health network positions it to capitalize on industry trends and meet patient demands.
  • Strong Leadership Team: An experienced leadership team provides strategic direction and operational expertise.
  • Comprehensive Healthcare Management Programs: Effective healthcare management programs improve quality metrics and patient satisfaction.

Potential Implications

Company Performance

  • Monitor Acquisition Integration: Closely track the integration of acquired businesses, particularly Prospect, to ensure realization of expected synergies and mitigate potential risks.
  • Strengthen Internal Controls: Address the identified material weakness in internal control over financial reporting to improve the reliability of financial statements.
  • Manage Regulatory Risks: Proactively address regulatory challenges and ensure compliance with healthcare laws and regulations.
  • Enhance Cybersecurity Measures: Invest in robust cybersecurity measures to protect sensitive data and prevent breaches.
  • Diversify Payer Base: Reduce reliance on key payers to mitigate concentration risk.

Stock Price

  • The higher P/E ratio suggests the stock may be overvalued, or that investors expect high growth.
  • The lower P/S ratio suggests it may be undervalued relative to its revenue.
  • The lower EV/EBITDA ratio suggests it may be undervalued relative to its earnings.

Astrana Health, Inc. (ASTH) SEC Filing Report – Form 10-K (FYE 2024)

Executive Summary

This report analyzes Astrana Health, Inc.’s 2024 Form 10-K, focusing on financial performance, key risks, and strategic initiatives. Astrana Health, a provider-centric, technology-powered, risk-bearing healthcare company, operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company reported revenue growth, driven by acquisitions and increased managed lives. Key risks include those related to the proposed acquisition of Prospect Medical Holdings, regulatory compliance, and cybersecurity. The overall assessment is cautiously optimistic, with a “Hold” recommendation, pending successful integration of acquisitions and effective risk management.

Company Overview

Astrana Health, Inc. (ASTH) is a healthcare company focused on value-based care. It operates an integrated healthcare delivery platform, enabling providers to participate in risk-bearing arrangements. The company’s business is divided into three segments:

  • Care Partners: Manages provider networks and facilitates value-based care arrangements.
  • Care Delivery: Operates primary and specialty care clinics, and ancillary service providers.
  • Care Enablement: Provides a technology platform and management services to support value-based care.

Recent developments include the proposed acquisition of certain assets and businesses of Prospect Medical Holdings, and the acquisition of Collaborative Health Systems (CHS).

Detailed Analysis

Management’s Discussion and Analysis (MD&A)

Management highlights the company’s combined clinical, administrative, and technology capabilities as a key strength. They emphasize diversification through subsidiaries and affiliated entities. The MD&A discusses the proposed acquisition of Prospect, noting potential benefits and risks. A key area of focus is the ACO REACH Model and its potential impact on revenue.

Financial Statement Analysis

Revenue

Total revenue increased by 47% from 2023 to 2024, driven by capitation revenue and risk pool settlements.

Revenue Type 2024 (in thousands) 2023 (in thousands) % Change
Capitation, net $1,856,785 $1,215,614 53%
Risk pool settlements and incentives $86,224 $63,468 36%
Management fee income $13,979 $38,677 -64%
Fee-for-service, net $62,331 $59,658 4%
Other revenue $15,221 $9,244 65%

Expenses

Operating expenses increased by 49%, primarily due to cost of services.

Expense Type 2024 (in thousands) 2023 (in thousands) % Change
Cost of services, excluding depreciation and amortization $1,763,152 $1,171,703 50%
General and administrative expenses $154,111 $112,597 37%
Depreciation and amortization $27,927 $17,748 57%

Profitability

Net income attributable to Astrana Health, Inc. decreased by 29% from 2023 to 2024. Adjusted EBITDA increased by 16%.

Metric 2024 (in thousands) 2023 (in thousands) % Change
Net income attributable to Astrana Health, Inc. $43,149 $60,717 -29%
Adjusted EBITDA $170,370 $146,587 16%

Key Ratios

  • Adjusted EBITDA Margin: 8% (2024) vs. 11% (2023)

Cash Flow

Cash flow from operating activities decreased, while cash flow from financing activities increased. Investing activities used significantly more cash in 2024 compared to 2023, primarily due to acquisitions.

Risk and Opportunity Assessment

Risks

  • Proposed Acquisition of Prospect: The acquisition is subject to regulatory approvals and bankruptcy court approval, creating uncertainty. Increased indebtedness to finance the transaction could limit financial flexibility.
  • Regulatory Compliance: The healthcare industry is heavily regulated, and non-compliance could result in penalties. Corporate practice of medicine laws could restrict the company’s business model.
  • Cybersecurity: Breaches of information security systems could lead to data exposure and disruption of business operations.
  • ACO REACH Model: Uncertainties in the design and administration of the ACO REACH Model could negatively impact results.
  • Reliance on Key Payers: A limited number of payers represent a significant portion of net revenue, creating concentration risk.

Opportunities

  • Shift to Value-Based Care: The industry’s move towards value-based and results-oriented models presents growth opportunities.
  • Integrated Health Network: The company’s integrated health network positions it to capitalize on industry trends and meet patient demands.
  • Strong Leadership Team: An experienced leadership team provides strategic direction and operational expertise.
  • Comprehensive Healthcare Management Programs: Effective healthcare management programs improve quality metrics and patient satisfaction.

Uncommon Metrics

The filing mentions several uncommon metrics that provide deeper insights:

  • Cash-to-Claims Ratio: A measure of financial solvency for risk-bearing organizations.
  • Risk Adjustment Factor (RAF) Scores: Used to determine payments from health plans based on patient health status.

Red Flags

  • Restatement of Financials: The company restated certain previously issued consolidated financial statements in August 2023, indicating potential weaknesses in internal controls.
  • IRS Examination: The company is currently under examination by the IRS for its 2019-2022 tax returns, creating potential for unanticipated tax liabilities.

Conclusion and Actionable Insights

Astrana Health demonstrates revenue growth and strategic expansion through acquisitions. However, the company faces significant risks related to the proposed acquisition of Prospect, regulatory compliance, and cybersecurity. The decrease in net income and Adjusted EBITDA margin warrants attention.

Overall Assessment: Hold

Recommendations:

  • Monitor Acquisition Integration: Closely track the integration of acquired businesses, particularly Prospect, to ensure realization of expected synergies and mitigate potential risks.
  • Strengthen Internal Controls: Address the identified material weakness in internal control over financial reporting to improve the reliability of financial statements.
  • Manage Regulatory Risks: Proactively address regulatory challenges and ensure compliance with healthcare laws and regulations.
  • Enhance Cybersecurity Measures: Invest in robust cybersecurity measures to protect sensitive data and prevent breaches.
  • Diversify Payer Base: Reduce reliance on key payers to mitigate concentration risk.

Financial Analysis of Astrana Health, Inc. (ASTH)

1. Commentary

Astrana Health’s financial performance in 2024 shows strong revenue growth, driven primarily by a significant increase in capitation revenue. However, net income attributable to Astrana Health, Inc. decreased by 29% compared to the previous year, despite an increase in Adjusted EBITDA. This decline in net income is due to an increase in interest expense and other expenses. The company continues to expand through acquisitions, impacting goodwill and intangible assets.

2. Financial Ratio and Metric Analysis

Profitability

Ratio/Metric 2024 2023 Change Trend Industry Comparison
Gross Profit Margin 14.23% 20.53% -6.30%

Metric: Calculated as (Total Revenue – Cost of Services) / Total Revenue.

Trend: Decreased from 20.53% in 2023 to 14.23% in 2024, a -6.30% change.

Industry: The average gross profit margin for the Healthcare sector is around 30-40%. Astrana’s margin is significantly lower, indicating higher costs relative to revenue.

Operating Profit Margin 4.39% 6.10% -1.71%

Metric: Calculated as Income from Operations / Total Revenue.

Trend: Decreased from 6.10% in 2023 to 4.39% in 2024, a -1.71% change.

Industry: The average operating profit margin for the Healthcare sector is around 10-15%. Astrana’s margin is lower, suggesting challenges in managing operating expenses.

Net Profit Margin 2.45% 4.17% -1.72%

Metric: Calculated as Net Income / Total Revenue.

Trend: Decreased from 4.17% in 2023 to 2.45% in 2024, a -1.72% change.

Industry: The average net profit margin for the Healthcare sector is around 5-10%. Astrana’s margin is below average, indicating that a smaller portion of revenue translates into profit.

Return on Assets (ROA) 3.69% 6.20% -2.51%

Metric: Calculated as Net Income / Total Assets.

Trend: Decreased from 6.20% in 2023 to 3.69% in 2024, a -2.51% change.

Industry: The average ROA for the Healthcare sector is around 4-8%. Astrana’s ROA is at the lower end, suggesting it is not generating as much profit from its assets compared to peers.

Return on Equity (ROE) 6.97% 9.85% -2.88%

Metric: Calculated as Net Income Attributable to Astrana Health, Inc. / Total Stockholders’ Equity.

Trend: Decreased from 9.85% in 2023 to 6.97% in 2024, a -2.88% change.

Industry: The average ROE for the Healthcare sector is around 10-15%. Astrana’s ROE is below average, indicating it is not generating as much profit from shareholders’ investments compared to peers.

Earnings Per Share (EPS) – Basic $0.91 $1.30 -30.00%

Metric: Calculated as Net Income Attributable to Astrana Health, Inc. / Weighted-Average Shares Outstanding (Basic).

Trend: Decreased from $1.30 in 2023 to $0.91 in 2024, a -30.00% change.

Industry: EPS varies widely. Need to compare to specific competitors.

Earnings Per Share (EPS) – Diluted $0.90 $1.29 -30.23%

Metric: Calculated as Net Income Attributable to Astrana Health, Inc. / Weighted-Average Shares Outstanding (Diluted).

Trend: Decreased from $1.29 in 2023 to $0.90 in 2024, a -30.23% change.

Industry: EPS varies widely. Need to compare to specific competitors.

Liquidity

Ratio/Metric 2024 2023 Change Trend Industry Comparison
Current Ratio 1.75 2.11 -17.06%

Metric: Calculated as Total Current Assets / Total Current Liabilities.

Trend: Decreased from 2.11 in 2023 to 1.75 in 2024, a -17.06% change.

Industry: A current ratio of 1.5 to 2 is generally considered healthy. Astrana’s current ratio is within this range, but the decrease indicates a slight weakening of short-term liquidity.

Quick Ratio (Acid-Test Ratio) 1.17 1.22 -4.10%

Metric: Calculated as (Total Current Assets – Inventory) / Total Current Liabilities. Assuming no inventory, calculated as (Total Current Assets) / Total Current Liabilities – (Medical Liabilities / Total Current Liabilities).

Trend: Decreased from 1.22 in 2023 to 1.17 in 2024, a -4.10% change.

Industry: A quick ratio of 1 or higher is generally considered good. Astrana’s quick ratio is slightly above 1, indicating reasonable short-term liquidity.

Cash Ratio 0.79 1.36 -41.91%

Metric: Calculated as (Cash and Cash Equivalents) / Total Current Liabilities.

Trend: Decreased from 1.36 in 2023 to 0.79 in 2024, a -41.91% change.

Industry: A cash ratio of 0.5 or higher is generally considered acceptable. Astrana’s cash ratio is below this benchmark, indicating a reliance on other current assets to meet short-term obligations.

Solvency/Leverage

Ratio/Metric 2024 2023 Change Trend Industry Comparison
Debt-to-Equity Ratio 0.61 0.46 32.61%

Metric: Calculated as Total Debt / Total Equity.

Trend: Increased from 0.46 in 2023 to 0.61 in 2024, a 32.61% change.

Industry: The average debt-to-equity ratio for the Healthcare sector is around 0.5-1. Astrana’s ratio is within this range, indicating a moderate level of leverage.

Debt-to-Assets Ratio 0.32 0.30 6.67%

Metric: Calculated as Total Debt / Total Assets.

Trend: Increased from 0.30 in 2023 to 0.32 in 2024, a 6.67% change.

Industry: The average debt-to-assets ratio for the Healthcare sector is around 0.3-0.6. Astrana’s ratio is within this range, indicating a moderate level of debt relative to its assets.

Interest Coverage Ratio (Times Interest Earned) 2.70 6.57 -58.90%

Metric: Calculated as Earnings Before Interest and Taxes (EBIT) / Interest Expense. EBIT = Net Income + Provision for Income Taxes + Interest Expense.

Trend: Decreased from 6.57 in 2023 to 2.70 in 2024, a -58.90% change.

Industry: A ratio of 3 or higher is generally considered safe. Astrana’s ratio is below this benchmark, indicating a potential risk in covering interest expenses.

Activity/Efficiency

Ratio/Metric 2024 2023 Change Trend Industry Comparison
Asset Turnover 1.50 1.49 0.67%

Metric: Calculated as Total Revenue / Total Assets.

Trend: Increased from 1.49 in 2023 to 1.50 in 2024, a 0.67% change.

Industry: The average asset turnover ratio for the Healthcare sector is around 0.8-1.2. Astrana’s ratio is higher, indicating efficient use of assets to generate revenue.

Valuation

Ratio/Metric 2024 Trend Industry Comparison
Price-to-Earnings Ratio (P/E) 32.89

Metric: Calculated as Stock Price / EPS (Basic). Stock Price = $29.34, EPS = $0.91.

Industry: The average P/E ratio for the Healthcare sector is around 20-30. Astrana’s P/E ratio is higher, suggesting it may be overvalued or that investors expect high growth.

Price-to-Book Ratio (P/B) 4.09

Metric: Calculated as Market Cap / Total Stockholders’ Equity. Market Cap = $29.34 * 47,929,872 = $1,406,209,447.28. Total Stockholders’ Equity = $712,720,000.

Industry: The average P/B ratio for the Healthcare sector is around 2-4. Astrana’s P/B ratio is within this range, indicating a reasonable valuation relative to its book value.

Price-to-Sales Ratio (P/S) 0.69

Metric: Calculated as Market Cap / Total Revenue. Market Cap = $29.34 * 47,929,872 = $1,406,209,447.28. Total Revenue = $2,034,540,000.

Industry: The average P/S ratio for the Healthcare sector is around 1-3. Astrana’s P/S ratio is lower, suggesting it may be undervalued relative to its revenue.

Enterprise Value to EBITDA (EV/EBITDA) 8.25

Metric: Calculated as (Market Cap + Total Debt – Cash and Cash Equivalents) / EBITDA. Market Cap = $29.34 * 47,929,872 = $1,406,209,447.28. Total Debt = $438,107,000. Cash and Cash Equivalents = $288,455,000. EBITDA = $127,334,000.

Industry: The average EV/EBITDA ratio for the Healthcare sector is around 10-15. Astrana’s EV/EBITDA ratio is lower, suggesting it may be undervalued relative to its earnings.

Growth Rates

Ratio/Metric 2024 2023 Change Trend
Revenue Growth $2,034,540 $1,386,661 47%

Metric: Calculated as (2024 Revenue – 2023 Revenue) / 2023 Revenue.

Trend: Revenue increased by 47% from 2023 to 2024.

Net Income Growth $49,932 $57,849 -14%

Metric: Calculated as (2024 Net Income – 2023 Net Income) / 2023 Net Income.

Trend: Net Income decreased by -14% from 2023 to 2024.

EPS Growth $0.91 $1.30 -30%

Metric: Calculated as (2024 EPS – 2023 EPS) / 2023 EPS.

Trend: EPS decreased by -30% from 2023 to 2024.

Other Relevant Metrics

  • **Adjusted EBITDA:** Astrana Health presents Adjusted EBITDA as a non-GAAP metric. It is calculated by adding back interest expense, interest income, provision for income taxes, depreciation and amortization, income from equity method investments, stock-based compensation, and other adjustments to net income. The company uses this metric to provide a clearer picture of its operating performance. Adjusted EBITDA increased by 16% from $146.59 million in 2023 to $170.37 million in 2024. While Adjusted EBITDA provides insights into operational profitability, it excludes significant expenses like interest and taxes, which are crucial for assessing overall financial health.
  • **Segment Performance:** The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. Care Partners is the largest segment, contributing the most to revenue and operating income. In 2024, Care Partners’ revenue increased by 52%, and operating income increased by 54%. Care Delivery’s operating income decreased significantly, while Care Enablement’s operating income decreased slightly.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️